Up-Regulation of MELK Promotes Cell Growth and Invasion by Accelerating G1/S Transition and Indicates Poor Prognosis in Lung Adenocarcinoma
Molecular Biotechnology · 2025
DOI: 10.1007/s12033-024-01143-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Qinggan Ni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burns and Plastic Surgery, Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, Yancheng, 2…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Nantong Municipal Commission of Health and Family Planning.
Abstract (Originalsprache)
Maternal embryonic leucine zipper kinase (MELK) is an oncogene in many tumors, although its contribution to lung adenocarcinoma (LUAD) is unclear. We examined MELK expression in patient LUAD tissue and matched healthy lung tissues. We investigated the connection between MELK expression and tumor differentiation, lymph node metastasis, and patient survival. We downregulated MELK expression using small-hairpin RNA to assess its impact on LUAD cell proliferation, clonogenicity, and invasion. We also investigated the molecular mechanism underlying these effects. MELK expression was significantly heightened in LUAD tissue as opposed to the matching healthy lung tissues. LUAD patients who had MELK overexpression had a worse prognosis. Suppression of MELK hinders proliferation, clonogenicity, and invasion of LUAD cells. The MELK suppression led to the arrest of the cell cycle's G1/S phase by reducing the cyclin E1 and cyclin D expression. Our outcomes manifest that MELK can function as a beneficial prognostic indication and a new therapy target for LUAD. MELK has an essential function in progressing LUAD, manifesting potential as a viable target for therapeutic intervention in this disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Burns and Plastic Surgery, Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, Yancheng, 224000, People's Republic of China.
- Department of Respiratory Diseases, The Sixth People's Hospital of Nantong (Affiliated Nantong Hospital of Shanghai University), Nantong, Jiangsu, 226011, People's Republic of China.
- Department of General Medicine, Affiliated Hospital of Nantong University, Yancheng Third People's Hospital, Yancheng, 224000, People's Republic of China.
- Department of Pathology, The Sixth People's Hospital of Nantong (Affiliated Nantong Hospital of Shanghai University), Nantong, Jiangsu, 226011, People's Republic of China.
- Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226011, People's Republic of China.
- Department of Respiratory Diseases, The Sixth People's Hospital of Nantong (Affiliated Nantong Hospital of Shanghai University), Nantong, Jiangsu, 226011, People's Republic of China. guanglin1983@hotmail.com.
Förderung
- Nantong Municipal Commission of Health and Family Planning
Zitieren
APA
Ni, Q., Miao, Y., Li, X., Yin, Z., Huang, H., Shi, G., & Shi, W. (2025). Up-Regulation of MELK Promotes Cell Growth and Invasion by Accelerating G1/S Transition and Indicates Poor Prognosis in Lung Adenocarcinoma. Molecular Biotechnology. https://doi.org/10.1007/s12033-024-01143-4
Vancouver
Ni Q, Miao Y, Li X, Yin Z, Huang H, Shi G, et al. Up-Regulation of MELK Promotes Cell Growth and Invasion by Accelerating G1/S Transition and Indicates Poor Prognosis in Lung Adenocarcinoma. Molecular Biotechnology. 2025. doi:10.1007/s12033-024-01143-4
BibTeX
@article{Ni2025,
author = {Ni, Qinggan and Miao, Yuqing and Li, Xia and Yin, Zhongbo and Huang, Hua and Shi, Guanglin and Shi, Weirong},
title = {Up-Regulation of MELK Promotes Cell Growth and Invasion by Accelerating G1/S Transition and Indicates Poor Prognosis in Lung Adenocarcinoma},
journal = {Molecular Biotechnology},
year = {2025},
doi = {10.1007/s12033-024-01143-4}
}
EUVIMED